Jubilant Pharmova: USFDA Classifies Spokane Facility as VAI
Jubilant Pharmova's subsidiary, Jubilant HollisterStier LLC's CMO facility in Spokane, Washington, USA, has been classified as 'Voluntary Action Indicated (VAI)' by the USFDA. This classification follows an inspection conducted between June 8-17, 2026. The company received the Establishment Inspection Report (EIR) on September 10, 2026.
The classification of a manufacturing facility by the USFDA, even as VAI, can have implications for ongoing operations, future approvals, and market perception. While VAI is less severe than OAI, it still requires attention and action from the company, potentially impacting its supply chain and regulatory standing.
The announcement states a regulatory classification by the USFDA, which is a factual update. While not explicitly positive or negative, a 'Voluntary Action Indicated' (VAI) classification is generally viewed as neutral to slightly positive as it indicates issues that the company is expected to address voluntarily, rather than a more severe 'Official Action Indicated' (OAI).
Jubilant Pharmova Limited has announced that the US Food and Drug Administration (USFDA) has concluded its review of the Establishment Inspection Report (EIR) for the inspection conducted at Jubilant HollisterStier LLC's CMO facility in Spokane, Washington, USA. The inspection took place from June 8, 2026, to June 17, 2026.
The USFDA has classified the facility as "Voluntary Action Indicated (VAI)". This classification follows an earlier disclosure dated June 19, 2026, regarding the USFDA inspection. Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is in turn a wholly owned subsidiary of Jubilant Pharma Limited, Singapore, and ultimately of Jubilant Pharmova Limited.
Jubilant HollisterStier LLC is a contract manufacturer specializing in sterile injectables and ophthalmics, serving the pharmaceutical and biopharmaceutical industries with facilities in North America. Jubilant Pharma Limited, based in Singapore, is an integrated global pharmaceutical company with businesses including Radiopharmaceuticals, Allergy Immunotherapy, and Contract Manufacturing.
What to do with a filing like this
Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.